Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

University of Calgary: Clinical Trials & FDA Approval Profile

University of Calgary (Global / Institutional) sponsors 65 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 33 active protocols (18 recruiting now), 6 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)9.2%
Median Closed Enrollment vs National (145 pts)35 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for University of Calgary
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)65
Active Pipeline (Recruiting Now)33 (18)
Completed vs Stopped Early6 / 6 (9.2%)
Median Closed Actual Enrollment35 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With University of Calgary
Hospital Research SiteLocationShared Protocols
University of CalgaryCalgary, Alberta24
University of AlbertaEdmonton, Alberta4

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by University of Calgary
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07687056ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632Phase IIIRECRUITING
NCT06320431ACT-GLOBAL THROMBOLYSIS (ACT-WHEN-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632Phase IIIRECRUITING

Explore interactive annual charts and M&A subsidiary rollups in the University of Calgary Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI